ABT: Symmetrical Triangle detected on 24 Jun 2026

ABT is forming a symmetrical triangle with converging support at $88.30 and resistance at $91.00, currently trading at $90.53 near the apex. The pattern structure scores 13/15, indicating well-defined trendlines and price compression. Breakout quality is solid at 11/13, though volume support is modest at 8/12 with current volume at 12.2M shares (87% of 20-day average). The overall 69/98 score reflects a tradeable but not exceptional setup. RSI at 54.34 shows neutrality—neither overbought nor oversold—while MACD histogram remains positive at 0.2259.

ABT trades 33.6% below its 52-week high of $135.76, reflecting sector-wide healthcare headwinds and company-specific challenges. Recent performance shows 1-month gains of 3.14% but 3-month losses of 13.12%. The Healthcare sector regime scores 0.33 (moderately bullish), while the broader market regime scores 0.9 (strongly bullish), creating a divergence. ABT's low beta of 0.47 suggests defensive positioning relative to the market. No major earnings announcements or catalyst events appear imminent in late June 2026. The stock's consolidation near the triangle apex follows a decline from higher valuations, typical of large-cap pharmaceutical names navigating pricing pressures and portfolio transitions.

A breakout above $91.00 resistance on expanding volume would project a conservative target of $94.64—approximately 4.6% upside from current levels. This measured move aligns with the triangle's height. The 60.04% win probability suggests slightly better-than-coin-flip odds for directional movement. Invalidation occurs below $88.30 support; a close below this level signals pattern failure and suggests further downside toward prior lows. Volume confirmation is critical—the 87% relative volume indicates breakout conviction is currently weak, so a successful move would require volume expansion above 14M+ shares.

Volume compression is a primary concern: current relative volume of 0.87 signals weak accumulation into the breakout. No catalyst appears imminent to spark directional commitment. ABT's 33% decline from 52-week highs raises questions about fundamental confidence in the name—check for recent analyst downgrades or earnings misses. The sector regime scores only 0.33 despite market-wide bullish conditions (0.9), indicating Healthcare underperformance that could cap ABT's upside even if technicals break higher. Beta of 0.47 means this stock lags in rallies. Watch for dividend sustainability given the price decline; ABT is a dividend aristocrat, and any cut would trigger institutional selling. No elevated volatility alerts present (20d vol at 27.89%), but tight consolidation occasionally produces false breakouts in low-volume scenarios.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.